BACKGROUND: Current strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD are limited by suboptimal performance and a narrow focus on only atherosclerotic CVD (ASCVD). We hypothesized that a strategy combining promising biomarkers across multiple different testing modalities would improve global and atherosclerotic CVD risk assessment among individuals without known CVD.
S
trategies for cardiovascular disease (CVD) risk assessment among adults without known CVD remain largely based on traditional atherosclerosis risk factors. 1 However, these risk prediction equations provide only moderate discrimination of atherosclerotic cardiovascular disease (ASCVD) risk. [1] [2] [3] Moreover, these algorithms typically do not consider risk for additional cardiovascular events, such as heart failure (HF) and atrial fibrillation, which are increasingly important contributors to the overall burden of CVD in the population. 4, 5 A growing body of evidence suggests that preventive interventions such as weight loss, exercise, and more aggressive blood pressure control may favorably impact ASCVD as well as these other highly relevant CVD outcomes. [6] [7] [8] Previous studies have evaluated individual novel risk markers in an attempt to improve CVD risk prediction and have identified several promising blood-and imaging-based biomarkers. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] However, for individual biomarkers, even those independently associated with outcomes, the incremental improvement in discrimination and risk classification is typically modest. 21, 22 As a result, investigators have explored combinations of biomarkers as a potential strategy to augment CVD risk prediction, with mixed results. [23] [24] [25] [26] [27] [28] It is important to note that these earlier studies have mostly combined biomarkers within the same testing modality, such as panels of genetic variants or circulating protein biomarkers, have frequently studied biomarkers with limited specificity for cardiovascular disease, and have included combinations of highly correlated biomarkers. 29 To our knowledge, no large studies have combined the most promising individual biomarkers across multiple different testing modalities in an attempt to create a risk prediction tool that augments traditional risk factor strategies.
We hypothesized that a panel combining nonredundant CVD biomarkers across multiple different testing modalities would overcome these limitations and improve CVD risk prediction. The tests prospectively selected included 12-lead ECG for assessment of left ventricular hypertrophy (ECG-LVH), [30] [31] [32] coronary artery calcium (CAC) measurement by computed tomography (CT), [11] [12] [13] and measurement of N-terminal probrain natriuretic peptide (NT-proBNP) [14] [15] [16] high-sensitivity cardiac troponin T (hs-cTnT) [17] [18] [19] [20] and high-sensitivity C-reactive protein (hs-CRP). 9, 10 These tests were selected because they reflect distinct and relevant pathological processes, multiple reports from population-based studies demonstrate independent associations of these measurements with CVD outcomes, and sufficient data exist from which to generate a priori thresholds to define abnormal test results.
METHODS

Study Populations
Study participants were included from examination 1 of the MESA (Multi-Ethnic Study of Atherosclerosis) and phase 1 of the DHS (Dallas Heart Study). Both MESA and DHS are ongoing, multi-ethnic, population-based cohort studies, with methods previously described. 33, 34 Between 2000 and 2002, MESA enrolled 6814 participants 45 to 84 years of age who were free from known CVD. For the present study, we excluded participants missing results from any of the 5 tests, with incomplete follow-up, or missing any of the covariates required for the multivariable analyses, resulting in a final study population of 6621, with complete data for all covariates ( Figure I in the online-only Data Supplement). A total of 3072 participants from DHS 30 to 65 years of age completed the 3 DHS phase 1 visits between 2000 and 2002, including a detailed in-home survey, laboratory testing, and imaging tests and ECG. For the present study, we excluded participants with prevalent CVD at baseline as well as those missing data on test results or covariates, or with incomplete follow-up, resulting in 2202 participants with complete data for all covariates ( Figure I in the online-only Data Supplement). MESA was approved by the Institutional Review Boards of the University of Washington and the participating sites, and DHS was approved by the Institutional Review Board of University of Texas Southwestern Medical Center. All participants provided written informed consent.
Data Collection and Variable Definitions
Race/ethnicity, history of CVD, and smoking status were self-reported. What Are the Clinical Implications?
• Our findings support the potential value of a multimodality testing strategy in selected individuals in whom additional risk stratification is desired beyond measurement of traditional atherosclerosis risk factors.
• Additional studies are needed to validate the present findings, determine the optimal approach to implementation, and address direct and indirect cost implications of the additional testing.
hypertension, diabetes mellitus, hypercholesterolemia, and low high-density lipoprotein cholesterol have been previously described for MESA 33 and DHS 35 and are based on conventional clinical definitions.
Multimodality Testing
LVH was determined from standard 12-lead ECGs using the Sokolow-Lyon voltage criteria and defined as present or absent. 36 In MESA, CAC scans were performed in duplicate using either electron beam or multidetector CT. 37 CAC scores were expressed in Agatston units, and the mean of the 2 scans was used. In DHS, CAC measurements were obtained from electron beam CT scans performed in duplicate 1 to 2 minutes apart as previously described. 38 To minimize false-positive CAC classifications because of tissue-associated artifact, a mean Agatston score >10 U was defined as CAC-positive status. 38 NT-proBNP and hs-cTnT were measured using the Cobas e601 in MESA and the Elecysys-2010 in DHS 18, 39 (both Roche Diagnostics). hs-CRP was measured using the BNII nephelometer (Dade Behring, Inc.) in MESA 40 and the Roche/Hitachi 912 System, Tina-quant assay (Roche Diagnostics) in DHS. 41 The following thresholds were prospectively selected to define elevated biomarker levels: NT-proBNP ≥100 pg/mL 42 hs-cTnT ≥5 ng/L (the limit of detection), 43 and hs-CRP ≥3 mg/L. 44 Values below the limit of blank of the hs-cTnT assay were arbitrarily assigned a level of 1.5 ng/L.
Cohort Follow-Up and End Point Collection
In MESA, participants were contacted by a telephone interviewer at 9-to 12-month intervals to inquire about hospital admissions, CVD diagnoses, and deaths. Medical records and death certificates were requested for all suspected cases, with records obtained in 98% of reported hospitalized CVD events. In DHS, fatal events were ascertained for all subjects using the National Death Index. Deaths were classified as cardiovascular if they included International Statistical Classification of Diseases, 10th Revision codes I00-I99. In the DHS, 2 overlapping approaches were used to capture nonfatal events: (1) a detailed health survey regarding interval cardiovascular events was administered by the Data Coordinating Center during annual calls to study subjects; and (2) for subjects providing informed consent (>90%), quarterly tracking was performed for hospital admissions using the Dallas-Fort Worth Hospital Council Data Initiative Database, which includes all hospital admission data for 70 out of 72 hospitals in the Dallas-Fort Worth area. Primary clinical source documents were collected and reviewed for all suspected nonfatal cardiovascular events in both MESA and DHS and were independently adjudicated by blinded end point committees. Follow-up data for both fatal and nonfatal events was complete through December 31, 2012, in MESA and December 31, 2011, in DHS.
Study End Points
The primary outcome was prospectively defined as time to the first event of a global CVD composite of cardiovascular death, myocardial infarction, stroke, coronary or peripheral revascularization >3 months after enrollment, incident HF, or atrial fibrillation. The major secondary end point was hard ASCVD events, including fatal or nonfatal myocardial infarction and fatal or nonfatal stroke. Tertiary end points included coronary heart disease (CHD) (fatal or nonfatal myocardial infarction), incident HF, all-cause mortality, and CVD mortality. The tertiary end points were evaluated with univariable analyses only in DHS because of the small numbers of these events, which precluded multivariable adjustment. A blanking period of 3 months for revascularization events was used to account for any influence of the study visit or CAC measurement on revascularization decisions.
Statistical Methods
All analyses were performed separately in MESA and DHS. The analysis strategy considered the test results as both continuous and categorical variables. In the continuous variable analyses, CAC, NT-proBNP, hs-cTnT, and hs-CRP were modeled as natural log-transformed continuous variables, with a value of 1 added to CAC because of the large numbers of zero values, and ECG-LVH was modeled as a dichotomous variable. In the categorical analyses, all variables were modeled as dichotomous variables using the prespecified cutpoints described previously. Associations of test results with study outcomes were assessed using unadjusted and adjusted Cox proportional hazards models, with all covariates determined a priori. The base model included traditional risk factors: age, sex, race/ethnicity, smoking status, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, blood pressure medications, and statin use. For the primary global CVD outcome, serum creatinine was included in the base model, and for the HF outcome, both creatinine and body mass index were included in the base model. 45, 46 The first multivariable model added individual test results to the base model, and the second model added all 5 of the test results to the base model. Assumptions for the Cox proportional hazards models were verified by Schoenfeld residuals.
Improvement in discrimination and reclassification for the primary global CVD outcome and the secondary ASCVD outcome was assessed by comparing the base model with the model that included the base model plus the 5 screening tests. Discrimination was assessed using Harrell's c-statistic, with confidence intervals determined by a jackknife resampling method. Improvement in the c-statistic was determined using bootstrap resampling. Integrated discrimination improvement, reflecting the difference in discrimination slopes between models with and without the markers, was determined using the failure probabilities from the Cox-proportional hazards models. 47 Category-free net reclassification improvement was performed for all end points according to methods described by Pencina et al. 48 Calibration of the global CVD and ASCVD models was assessed by the modified Hosmer-Lemeshow test for time-toevent data. For the primary analyses, coefficients were determined separately for each model in MESA and DHS. Sensitivity analyses were performed in which the full multivariable models with continuous biomarker coefficients from MESA were applied directly to the DHS cohort.
To facilitate clinical application of the multimodality strategy, a simple integer score counting the number of abnormal screening test results was created, with values ranging from 0 to 5. In MESA scores of 4 to 5 were collapsed, and in DHS scores of 3 to 5 were collapsed because of the small numbers of participants in the highest risk categories. Cumulative rates of the primary composite outcome were determined and displayed using the Nelson-Aalen failure estimator, with groups compared with the log-rank test. Multivariable adjusted Cox-proportional hazards analyses were performed, adjusting for the variables contained in the base model. A similar approach using the same integer score was used for secondary and tertiary end points. Unadjusted stratified analyses were performed in subgroups defined by sex, younger age (men <55, women <65), race/ethnicity (black, white, Hispanic), and estimated 10-year ASCVD risk <7.5% using the pooled cohort equations. 1 Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Inc.), and all P values are 2-sided with an alpha of 0.05. Published SAS macros were used to assess measures of fit. 49 
RESULTS
Participant characteristics are detailed in Table 1 . Median age at enrollment was 62 years in MESA and 44 years in DHS. In MESA, over a median 11 years of follow-up, 1026 global CVD events occurred, including 486 ASCVD events. In the DHS, over a median follow-up period of 10.3 years, 179 global CVD events occurred, including 96 ASCVD events. The prevalence of abnormal results on the 5 tests in MESA and DHS is shown in Table 1 and ranged from 9% for ECG-LVH (in both cohorts) to 45% for hs-CRP (in DHS). The individual test results were not highly correlated in either MESA or DHS (Tables I and  II in 
Associations of Test Results With Outcomes
In MESA, each of the 5 tests was associated with the primary global CVD outcome after adjustment for traditional risk factors and the other test results, with results consistent whether the tests were considered as continuous variables or using the prospective dichotomous cutpoints (Table 2 ). Findings replicated in DHS, with the exception that hs-CRP was not independently associated with global CVD after multivariable adjustment ( Table 2) . Associations of the test results with the secondary composite ASCVD outcomes are shown in Table 3 . In MESA, each of the test results except hs-CRP was independently associated with ASCVD. In DHS, associations of hs-CRP and hs-cTnT with ASCVD were attenuated after adjustment for risk factors (Table 3) . Associations of the screening tests with tertiary end points were largely concordant in MESA and DHS, with variation seen depending on which end point was evaluated (Tables III-VI in the online-only Data Supplement). CAC was most strongly associated with coronary heart disease events, followed by NT-proB-NP and hs-cTnT, with no association seen for ECG-LVH or hs-CRP (Table III in est hazard ratio for fatal outcomes, followed by hs-cTnT. ECG-LVH associated with CVD mortality but not all-cause mortality (Tables III-VI in the online-only Data Supplement).
Evaluation of Risk Prediction Metrics
Addition of the 5 tests to the base model improved the c-statistic for global and ASCVD in both DHS and MESA and for each of the tertiary end points in MESA (P<0.01 for each; Table 4) , with the largest increase in c-statistic seen for the global CVD and HF end points. Addition of the test results also resulted in significant category-free net reclassification improvement and integrated discrimination improvement for the global CVD end point in both MESA and DHS (Table 4) . Models including the 5 tests were well calibrated in both MESA and DHS for both global and ASCVD end points (Figures II and III in the onlineonly Data Supplement). In exploratory analyses focusing only on the ASCVD end point in MESA, the largest improvement in risk prediction metrics was observed when CAC was added to the base model, with modest but significant increments beyond CAC in the c-statistic, net reclassification improvement, and integrated discrimination improvement observed for the addition of NT-proBNP and hs-cTnT but not for the addition of ECG-LVH or hs-CRP (Table VII in the online-only Data Supplement).
In sensitivity analyses, the MESA base models and models including all 5 test results were applied directly to DHS using coefficients for all variables derived from MESA. In these analyses, both base and fully adjusted models had lower c-statistics than the models in which the coefficients were derived in the DHS dataset. However, improvements in the c-statistic, net reclassification improvement, and integrated discrimination improvement were similar using the 2 modeling strategies ( 
Multimodality Risk Score
Participants were assigned 1 point for each abnormal test result, yielding an integer score ranging from 0 to 5. The proportion of individuals with scores of 0, 1, 2, 3, or ≥4 was 20%, 30%, 27%, 17%, and 6% in MESA and the proportion with scores of 0, 1, 2, and ≥3 in DHS was 35%, 42%, 17%, and 7%, respectively (Figure V in the online-only Data Supplement). A >20-fold gradient of risk for both global CVD and ASCVD was observed across higher scores in both MESA and DHS (Figure 1 ). In MESA, participants with scores ≥2 comprised <50% of the cohort but accounted for 79% of the events. In the younger DHS population, participants with a score ≥2 comprised 24% of the cohort but accounted for 58% of events ( Figure V in the online-only Data Supplement).
In both MESA and DHS, consistent graded associations with global CVD and ASCVD risk were seen with increasing scores across sex and race/ethnic subgroups and in younger and lower risk individuals (Figure 2 , Figure VI in the online-only Data Supplement).
As expected, higher scores were associated with a greater burden of traditional risk factors (Tables IX and  X in the online-only Data Supplement). However, in multivariable analyses accounting for traditional risk factors, compared with those with a score of 0 in MESA, CVD risk increased among participants with a score of 1 (hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.4-2.6), 2 (HR, 3.2; 95% CI 2.3-4.4), 3 (HR, 4.7; 95% CI 3.4-6.5), and ≥4 (HR, 7.5, 95% CI, 5.2-10.6) (Figure 3 ). Similar graded associations across higher scores were seen for the secondary ASCVD end point and with tertiary end points, with findings most robust for incident HF (Figure 3 ). In the DHS, higher scores were also associated with global CVD, ASCVD, and all-cause mortality in the fully adjusted models ( Figure VII in the online-only Data Supplement).
DISCUSSION
In the present study, we combined 5 promising tests for cardiovascular risk stratification among adults without known CVD: the 12-lead ECG to assess LVH, CAC scanning, and measurement of NT-proBNP, hs-cTnT, and hs-CRP. Although this combination of tests captures multiple well-defined cardiac pathological processes, including cardiac hypertrophy, coronary atherosclerosis, neurohormonal activation, cardiomyoctye injury, and inflammation, to our knowledge they have not been considered together previously. Each test provided nonredundant incremental information to traditional risk factors, and when the test results were combined in a simple integer score, a >20-fold gradient in risk for the primary global CVD outcome was seen across the range of scores after >10 years of follow-up. The findings were consistent among women, ethnic minorities, younger individuals, and those at low predicted risk for ASCVD. Results were robust to multivariable adjustment and across different CVD end points, and replicated in 2 distinct cohorts with different age ranges and race/ethnic distributions. Discrimination and risk classification were improved for both global and ASCVD outcomes, and models incorporating the screening test results were generally well calibrated. These findings provide strong evidence that a simple strategy including the most promising biomarkers from several different testing modalities substantially improves CVD risk prediction among individuals without known CVD. CVD risk stratification has traditionally been focused on predicting only CHD events. More recently, in concert with changes in prevention guidelines, 1,50 the focus of CVD risk prediction has expanded to include stroke. It is notable that although rates of myocardial infarction and stroke have been steadily declining, 51 the prevalence of HF is projected to increase by 25% over the next 20 years. 4 Among middle-age adults, the 10-year risk of incident HF is ≈10%, 52 with lifetime risks of 30% to 40%. 53 Tools to predict incident HF may allow targeted therapies to prevent its development, which could have important public health implications given its associated morbidity and mortality. To date only a single global CVD risk model has been developed that considers ASCVD and HF together 54 and differs from our approach because it only contained traditional CHD risk factors as covariates and did not include atrial fibrillation as part of the global CVD outcome. 54 Like HF, atrial fibrillation is rapidly increasing in prevalence, is difficult to treat once present, and carries substantial costs and morbidity. 5, 55 A focus on global CVD risk prediction, incorporating end points of HF and atrial fibrillation as was done in the present study, is likely to become increasingly important. It is important to note that global CVD risk assessment should be considered as a complement and not a replacement for cause-specific risk estimation (ie, for ASCVD).
Although the individual biomarkers were each associated with the primary composite global CVD end point, they differed in their relative associations with secondary and tertiary CVD end points, as would be expected on the basis of the pathological processes captured by each biomarker. 11, 15, 18, 31, 39 For example, CAC demonstrated the largest HR for ASCVD and CHD events, whereas NT-proBNP and hs-cTnT were associated with the highest hazards for all-cause and CVD mortality and HF. It is notable that although NT-proBNP and hs-cTnT were included to enhance global CVD risk prediction, they also provided independent prognostic value for AS-CVD and CHD in MESA. While hs-CRP provided modest incremental information for the global CVD and HF end points, this biomarker generally demonstrated the weakest and least consistent associations across the portfolio of end points. Further, the multimodality strategy provided robust discrimination and reclassification for ASCVD and global CVD events. Thus, this strategy may contribute to more accurate identification of appropriate candidates for ASCVD preventive therapies while capturing risk for broader CVD events. Several limitations of the present study merit consideration. First, this study was not designed to determine the optimal number or combination of the screening tests for risk stratification purposes. The number of potential combinations of the 5 tests is 120, and each potential combination could be considered for multiple end points. Second, the number of end points in the DHS was too low to perform multivariable adjustment for the tertiary end points. However, the adjusted results for the primary and secondary outcomes demonstrated consistent results compared with MESA, as did unadjusted analyses for the tertiary end points. Last, we acknowledge that comparing strength of association between the different tests presents challenges and can be influenced by the incidence of the different end points and distributions of the test results in the study cohorts.
The goal of our study was to evaluate prospectively a multimodality risk prediction strategy and replicate the findings in a second population-based dataset. We did not design our primary analyses to validate the MESA multivariable models in DHS but rather to determine whether the scientific approach replicated in a second dataset. We did perform sensitivity analyses in which the MESA models were applied directly to the DHS. Although the overall performance of the models was modestly impacted (as would be expected), the improvement in model performance with the addition of the 5 tests was generally similar to the primary analysis approach in which the coefficients were derived in the DHS. The models from MESA were also less well calibrated when applied to DHS, particularly for the ASCVD end point, although calibration remained adequate. Additional prospective validation is required before the multivariable models can be considered for clinical application.
Clinical Implications
Current consensus recommendations support only selective additional testing beyond traditional cardiovascular risk factors. 1, 22 However, combinations of tests were not assessed in these guidelines, and the gradients of risk seen with the individual tests considered in these documents were not as large in magnitude as those seen with the multimodality risk score in the current study. Our robust findings support the potential value of a multimodality testing strategy using these markers in selected individuals in whom additional risk stratification is desired.
The multimodality testing strategy may help to individualize and more efficiently target cardiovascular prevention efforts in primary care. Although current prevention guidelines recommend a risk-based approach only when implementing statin and aspirin therapy, the role for targeting therapy on the basis of risk in primary prevention is likely to expand in the future. For example, the SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated that lowering blood pressure below currently recommended targets was associated with reduced rates of HF and all-cause mortality, 8 end points that were predicted well by the tests studied here. The favorable effects of more aggressive blood pressure lowering in SPRINT were balanced by side effects and some safety concerns, and the resource implications of broad implementation of lower blood pressure targets would be substantial. In addition, a novel agent for the management of diabetes mellitus, empagliflozin, Hazard ratios (HR) represent comparisons versus participants with zero abnormal test results. No significant interactions were seen across subgroups (P>0.05 for each). Younger age is defined as <55 years of age in men and <65 years of age in women. Low estimated risk is defined as 10-year estimated ASCVD risk <7.5% using the pooled cohort equations.
recently demonstrated a 38% reduction in death from cardiovascular causes and 35% reduction in HF, with lesser impact on ASCVD end points. 56 Targeting empagiflozin to patients at highest risk for death and HF events may be a prudent strategy given the high cost of the drug. Thus, an individualized, risk-based approach using traditional risk factors plus biomarkers may be appropriate when determining blood pressure targets or implementing newer therapies that favorably impact CVD end points beyond ASCVD.
The multimodality strategy could also facilitate targeting of global and disease-specific CVD prevention efforts as population health care becomes an increasing focus of healthcare delivery. For example, among individuals with a risk score of 0, global CVD risk was extremely low in both MESA and DHS (<3% over 10 years in each study), and this large group of individuals could be managed with a low-intensity/low-cost approach. In contrast, higher scores clearly captured risk not recognized with traditional risk factor algorithms, as consistent results were seen even among individuals estimated to be at low risk with the pooled cohort equations. Individuals with scores ≥2, for example, represented ˂50% of MESA participants and 25% of the younger DHS cohort, yet accounted for 79% and 58% of global CVD events, respectively. A tailored and incrementally more intensive approach to global CVD risk reduction would be appropriate for individuals with a greater number of abnormal test results. For example, higher risk individuals could be referred to lifestyle intervention programs, focusing on improving low fitness and obesity, which are important contributors to multiple components of the global CVD end point. Triage for cardiovascular specialist evaluation may be considered for the highest risk individuals, a strategy recently evaluated for a biomarker screening program in primary care with promising preliminary results. 57 Although each of the 5 tests is available clinically and thus measurement is currently feasible, larger studies will be needed to validate the present findings and elucidate the optimal strategy for clinical implementation. Moreover, additional consideration of costs, both those directly related to the tests and those engendered by abnormal test results, would be necessary before implementation. Hazard ratios (HR) represent comparisons versus participants with zero abnormal test results. All models were adjusted for age, sex, race, smoking status, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure and blood pressure medications, and statin medications. The global CVD and mortality models were also adjusted for serum creatinine, and the heart failure models were additionally adjusted for body mass index and creatinine. ASCVD indicates atherosclerotic CVD; CHD, coronary heart disease; CHF, congestive heart failure; CV, cardiovascular; and CVD, cardiovascular disease.
CONCLUSION
A novel multimodality CVD risk assessment strategy using the nonredundant markers of ECG-LVH, CAC, NTproBNP, hs-cTnT, and hs-CRP substantially improved global and atherosclerotic CVD risk stratification among individuals from the general population free from CVD at study entry. Additional study of preventive strategies incorporating these complementary tests is indicated.
ACKNOWLEDGMENTS
The authors thank the other investigators as well as the staff and participants of the Multi-Ethnic Study of Atherosclerosis and Dallas Heart Study studies for their valuable contributions. A full list of participating Multi-Ethnic Study of Atherosclerosis investigators and institutions can be found at http://www. mesa-nhlbi.org.
SOURCES OF FUNDING
This study was funded by research grant CA03801 awarded to Dr de Lemos from the National Space Biomedical Research Institute. The Multi-Ethnic Study of Atherosclerosis was supported by R01 HL071739 and contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, and N01 HC 95169 from the National Heart, Lung, and Blood Institute. The Dallas Heart Study was funded by a grant from the Donald W. Reynolds Foundation. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001105 to the University of Texas Southwestern Medical Center. Biomarker measurements were supported by investigator-initiated grants to Drs de Lemos and DeFilippi from Roche Diagnostics. Roche Diagnostics had no role in the design and conduct of the study and did not participate in analysis or interpretation of the data. They were not provided a summary report of the data and have not reviewed this submission.
DISCLOSURES
Dr de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics, and consulting income from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Prevencio, Diadexus, Siemen's Healthcare, Radiometer, and Amgen. Dr DeFilippi has received research support from Roche Diagnostics, Abbott Diagnostics, and Critical Diagnostics, and consulting fees or honoraria from Roche Diagnostics, Siemens Healthcare Diagnostics, Thermo-Fisher, and Radiometer. Dr Wang has received consulting fees from Ultragenyx. Dr Seliger has received grant support from Roche Diagnostics. Dr Budoff has received grant support from General Electric. Dr Ballantyne has received grant support from Roche Diagnostics and Abbott Diagnostics, and has a provision patent (filed by Baylor College of Medicine and Roche) for the use of biomarkers to improve the prediction of heart failure.
